Annual Report of TBCR (2023)

Dear all,

We are pleased to share with you the 2023 annual report of Translational Breast Cancer Research (TBCR). In 2023, with the joint effort and support of all contributors, TBCR made great progress with the publication of 33 articles, and increased website pageviews and visitors. For more details, please see the following report.

Read More>>

Reviewer of the Month (2023)

In 2023, many TBCR reviewers make outstanding contributions to the peer-review process. They demonstrated professional effort and enthusiasm in their reviews and provided comments that genuinely help the authors to enhance their work.

Hereby, we would like to highlight some of our outstanding reviewers, with a brief interview of their thoughts and insights as a reviewer. Allow us to express our heartfelt gratitude for their tremendous effort and valuable contributions to the scientific process.

Read More>>

Interviews with Outstanding Authors (2023)

In 2023, many TBCR authors make outstanding contributions to our journal. Their articles published with us have received very well feedback in the field and stimulate a lot of discussions and new insights among the peers.

Hereby, we would like to highlight some of our outstanding authors who have been making immense efforts in their research fields, with a brief interview of their unique perspective and insightful view as authors.

Read More>>

New-generation technologies for spatial tissue analysis, indispensable tools for deciphering intratumor heterogeneity in the development of antibody-drug conjugates and radio-immunoconjugates for cancer treatment

One example of ROIs for spatial tissue analysis by GeoMx^® DSP, (NanoString Technologies, Seattle, WA, USA). A section (4 µm) of a formalin-fixed, paraffin-embedded TMA containing samples of non-small cell lung cancer was stained by immunofluorescent morphology markers: green, pan-cytokeratin; red, CD45RO (pan-leucocyte marker); blue, DAPI (DNA/nuclear marker), and scanned by the instrument. ROI selection was performed using the instrument’s in-built software.

Read More>>

Interaction of de novo cholesterol biosynthesis and Hippo signaling pathway in ductal carcinoma in situ (DCIS)—comparison with the corresponding normal breast epithelium

Schematic depiction of the interaction between small GTPase and Hippo signaling pathways. The core of the Hippo pathway consists of a kinase cascade where STK3 in complex with its regulatory protein SAV1, phosphorylates and activates LATS1 in complex with its regulatory protein MOB1A, which, in turn, phosphorylates and inactivates YAP. Phosphorylation of YAP by LATS1 inhibits its translocation into the nucleus, the formation of the complex with TAZ, the binding to TEAD, and the transcription of several genes involved in cell proliferation, death, and migration.

Read More>>

Biomarkers derived from CmP signal network in triple negative breast cancers

CmP signal network-based biomarker discovery and therapeutic application. The depicted model showcases our current comprehension of the CmPn/CmP signal network’s role in breast cancer tumorigenesis, emphasizing the importance of mPRs in facilitating the continued influence of progesterone on both genomic and non-genomic actions. Investigating this network further holds potential for discovering innovative therapeutic strategies and prognostic biomarkers that specifically target the CmP signaling pathways in TNBC.

Read More>>

Features and applications of Ehrlich tumor model in cancer studies: a literature review

Sequence of EC manipulation for inoculation and AEC and SEC development. EC, Ehrlich cell; AEC, ascitic Ehrlich carcinoma; SEC, solid Ehrlich carcinoma.

Read More>>

CDK4/6 inhibitors for primary endocrine resistant HR-positive/HER2-negative metastatic breast cancer: a case report

CT scan showing liver metastasis size before and after treatment: (A) 2022.02 baseline CT scan; (B) 2023.02 evaluation CT: after 12+ months of treatment with fulvestrant + abemasilib. CT, computed tomography.

Read More>>